This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

YMI ... WTF?

ONTARIO, Canada ( TheStreet) --What or who is responsible for the big-time selloff in YM Biosciences (YMI)?

Beginning a column with a question is lame -- I'm supposed to be providing answers, after all -- but in this case, nailing down an explanation for why YM Bio has shed 33% of its market value in the past week is proving very difficult. [YM Bio shares were up 3 cents to $1.14 in Tuesday trading.]

The volatility in YM Bio is particularly unnerving because new and important clinical data on the company's myelofibrosis drug CYT387 is scheduled for presentation at the American Society of Hematology annual meeting, which runs Dec. 10-13.

CYT387 is a controversial, at least by Wall Street's standards, due to early data presented last spring suggesting the drug may be effective in treating anemia associated with myelofibrosis. That's something Incyte's (INCY - Get Report) Jakafi, which recently won FDA approval for the cancer-like bone marrow disease, cannot do.

Incyte sports a $1.5 billion market valuation thanks in large part to Jakafi's commercial potential. But if YM Bio's CYT387 is a superior myelofibrosis drug, even being two or three years behind in development, the company's $132 million market cap makes it hugely under-valued.

Yet YM Bio shares are tanking. Here are three possible explanations, in order of plausibility, culled from various discussions with investors and other sources over the past few days. I have nothing confirmed but the truth probably lies somewhere below:

1. A large hedge fund is being forced to sell YM Bio (along with other low-conviction long positions) after being caught short in Pharmasset, which obviously skyrocketed in value when Gilead Sciences announced the $11 billion takeover.

Yes, I've heard the name of the hedge fund allegedly forced to sell YM Bio shares, but I can't confirm so I won't share. The top-five hedge fund holders of YM Bio at the end of the September quarter were (in order) Healthcor Management, Baker Brothers Advisors, Balyasny Asset Management, Discovery Capital Management and Deerfield Management.

The high volume of YM Bio shares being sold, including 7.6 million shares on Nov. 22 and 3.7 million shares Monday, suggests the forced seller is likely to be one of the hedge funds listed above.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
INCY $70.87 -0.06%
AAPL $94.41 -0.63%
FB $100.38 0.63%
GOOG $690.37 1.10%
TSLA $150.10 1.40%


Chart of I:DJI
DOW 15,929.42 -97.63 -0.61%
S&P 500 1,844.65 -8.79 -0.47%
NASDAQ 4,269.0260 -14.7270 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs